Atazanavir Sulfate CAS 229975-97-7 Purity ≥99.0% API Factory Anti-HIV HIV-1 Protease Inhibitor

Atazanavir Sulfate (BMS-232632 Sulfate) (CAS: 229975-97-7) is a sulfate salt form of atazanavir that is a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration. Atazanavir Sulfate is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp). Atazanavir Sulfate is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM. Atazanavir Sulfate is an azapeptide and HIV-protease inhibitor that is used in the treatment of HIV infections and AIDS in combination with other Anti-HIV Agents, has been developed and launched by Bristol-Myers Squibb (BMS), under worldwide license from Novartis, for the treatment of HIV infection. Atazanavir was launched in the US as Reyataz™ in July 2003. Antiviral. Atazanavir has shown to be generally more potent than the five currently approved HIV-1 protease inhibitors. Atazanavir selectively inhibits the virus-specific processing of viral Gag and Gag-Pol polyproteins in HIV-1 infected cells by binding to the active site of HIV-1 protease, thus preventing the formation of mature virions. Atazanavir is not active against HIV-2.